Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

All told, the transaction should be construed as bullish. If the options holder did not confidently expect an increase in the share price, there would be no incentive to exercise the options early and pay the immediate tax liability.

Dew, it does sound bullish to me. However, what would really bullish is excellent anti-viral effects of EDP-235 in the phase 2 trial with minimal safety issues. I would also like to see some news that the HepB program using EDP-514 in with a new in house compound or an outside one being used in combination with EDP-514 and a nuc inhibitor. It has been a while since we heard anything in that area.